Recent developments focus on clinical trial progress, capital raises, and regulatory compliance.

• AIM dosed the last patient early in the Phase 2 DURIPANC study for Ampligen in treating pancreatic cancer as of August 2026 [N1].
• The company advanced the Phase 2 DURIPANC study and anticipates topline data in Q1 2027 [N3].
• AIM ImmunoTech regained NYSE American compliance with increased stockholders' equity as of June 2026 [N4].
• The company unveiled a $2.4 million direct offering and private placement of warrants in May 2026 [N5].
• Multiple equity transactions in the first half of 2026 raised approximately $10.4 million in gross proceeds [S1][S2].
• AIM announced changes to key dates and terms related to a rights offering in January 2026 [N7][N8].

The company has advanced clinical trials for Ampligen in pancreatic cancer, a large unmet medical need with limited competition. Intellectual property protections and orphan drug designations provide market exclusivity potential. Recent equity raises have improved liquidity and NYSE compliance, supporting ongoing development. Successful clinical outcomes could enable progression to pivotal trials and potential partnerships or acquisitions in the oncology space.

AIM faces risks typical of clinical-stage biotech companies, including clinical trial failures, regulatory hurdles, and limited revenue generation. The company depends on a small number of suppliers and contract manufacturers, which could disrupt production. Significant dilution risk exists due to numerous outstanding warrants and equity issuances. Operating losses and cash burn require continued capital raises, which may not be available on favorable terms. Market acceptance and reimbursement for Ampligen remain uncertain.

AIM ImmunoTech's moat is primarily based on its intellectual property portfolio protecting Ampligen's use in pancreatic cancer and other indications, including patents in major markets and orphan drug designations. The company's clinical data and ongoing trials contribute to its competitive positioning. However, as a clinical-stage biotech, the moat is contingent on successful clinical development, regulatory approvals, and establishing manufacturing and commercial capabilities. The limited number of suppliers and manufacturing partners may also create operational dependencies.

• Clinical Development Risk: Ampligen is in early-stage clinical trials with uncertain outcomes; failure to demonstrate safety and efficacy could impair business prospects.
• Regulatory Approval Risk: Ampligen is not approved by the FDA; regulatory delays or denials could limit commercialization opportunities.
• Supply Chain Risk: Dependence on limited third-party manufacturers and suppliers without long-term agreements may cause production delays or increased costs.
• Financial and Dilution Risk: The company has incurred operating losses and relies on equity financing; outstanding warrants and equity issuances pose dilution risk to shareholders.
• Market and Commercialization Risk: Even if approved, market acceptance, pricing, and reimbursement for Ampligen are uncertain, affecting potential revenue.

• AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida, focused on developing Ampligen for late-stage pancreatic cancer treatment [S1].
• The company's flagship product is Ampligen (rintatolimod), a double-stranded RNA molecule under development for cancers, viral diseases, and immune system disorders. Ampligen is approved for commercial sale in Argentina for severe Chronic Fatigue Syndrome but not approved by the FDA in the US [S1].
• AIM is conducting clinical trials evaluating Ampligen's efficacy and safety in pancreatic cancer, including a Phase 2 DURIPANC study combining Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) [S1].
• The DURIPANC Phase 2 study is an investigator-initiated, open-label, single-center study enrolling up to 25 subjects, with the primary objective being clinical benefit rate of the combination therapy [S1].
• The company has completed dosing the last patient early in the Phase 2 DURIPANC study as of August 2026 [N1].
• AIM has intellectual property protections including broad combination therapy patents in the US, Japan, and Europe, and orphan drug designations in the US and EU for pancreatic cancer [S1].
• The company also explores Ampligen's antiviral activities and potential use as prophylactic or treatment for viruses, and as a vaccine adjuvant in combination with AstraZeneca's FluMist [S1].
• AIM's revenue is minimal, with $26,000 reported for the quarter ended June 30, 2026, and net loss of $3.788 million for the same period [S2].
• As of June 30, 2026, AIM had cash and cash equivalents of $9.9 million and current assets of $10.4 million against current liabilities of $4.95 million, resulting in a current ratio of 2.11 and cash ratio of 2.24 [S2].
• The company completed multiple equity transactions in the first half of 2026, including a rights offering raising approximately $1.8 million and other offerings raising aggregate gross proceeds of about $10.4 million [S1][S2].
• AIM regained NYSE American compliance with increased stockholders' equity as of June 2026 [N4].
• The company has a significant number of outstanding warrants (approximately 48.5 million as of June 30, 2026) which could cause dilution if exercised [S2].
• AIM's board and executive officers have diverse backgrounds with expertise in leadership, biotech, legal, regulatory, and finance [S1].
• The company relies on third-party manufacturers for Ampligen production, including Jubilant HollisterStier LLC and Pharmaceutics International Inc. for fill and finish services, with limited long-term supply agreements [S1].
• AIM's research and development expenses include clinical studies, manufacturing, quality control, and regulatory costs, with $3.924 million spent in 2025 [S1].
• The company faces risks related to limited suppliers, regulatory approvals, potential dilution from equity issuances, and operational challenges typical of clinical-stage biotech companies [S1][S2].